Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study

Autor: Mark T. Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Cedric Hermans

Publikováno v: Therapeutic Advances in Hematology, Vol 14 (2023)

Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date on ef

Externí odkaz: https://doaj.org/article/3106ae96a0814ef99d906c776d898f7c

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature

Autor: Shadan Lalezari, Assaf A. Barg, Rima Dardik, Jacob Luboshitz, Dalia Bashari, Einat Avishai, Gili Kenet

Publikováno v: TH Open, Vol 05, Iss 02, Pp e183-e187 (2021)

Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood. Methods Medical

Externí odkaz: https://doaj.org/article/4483145807e0428c90908a643c4f5166

Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A

Autor: Pål Andre Holme, Karina Meijer, Claude Negrier, Shadan Lalezari, Ingrid Pabinger, Monika Maas Enriquez, Maria Wang, Lone Hvitfeldt Poulsen, Mark T. Reding, Pavani Chalasani, Maria Elisa Mancuso

Publikováno v: Haemophilia, 27(3), E347-E356. Wiley
Reding, M T, Pabinger, I, Holme, P A, Poulsen, L, Negrier, C, Chalasani, P, Maas Enriquez, M, Wang, M, Meijer, K, Mancuso, M E & Lalezari, S 2021, ' Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A : final results of the PROTECT VIII extension study ', Haemophilia, vol. 27, no. 3, pp. e347-e356 . https://doi.org/10.1111/hae.14297

Introduction: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to extend its half-life. Aim: To re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65fe46cdd05e2e5c47cfc2c11d9447fd
https://doi.org/10.1111/hae.14297

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

Autor: Nikki Church, Despina Tseneklidou-Stoeter, Elena Santagostino, Shadan Lalezari, Johnny Mahlangu, Maria Fernanda Lopez Fernandez, Horst Beckmann

Publikováno v: European Journal of Haematology

Objectives BAY 81‐8973 (Kovaltry®), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1‐year LEOPOLD I trial. The LEOPOLD I extension evaluated long‐t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9337a856d170e7aef97d873b01f72156
https://doi.org/10.1111/ejh.13402

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses

Autor: Tami Livnat, Yulia Khavkin, Gili Kenet, Einat Avishai, Assaf A. Barg, Shadan Lalezari, Ivan Budnik, Rima Dardik, Sarina Levy-Mendelovich, Ortal Barel

Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 9074, p 9074 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 16

Introduction: Hemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency or dysfunction due to F8 gene mutations. HA carriers are usually asymptomatic because their FVIII levels correspond to approximately half of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa2bf17b9e8f618a006cdc666ea2098
https://www.mdpi.com/1422-0067/22/16/9074